Note: Eligibility for Samsung’s SmartStarts program requires newcomers to possess* one of the following Immigration, Refugees ...

Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of 2025 that it hopes will show greater weight-loss, after posting ...

Novo Nordisk plans a new trial for its experimental drug, CagriSema, in 2025 after recent trials failed to meet weight-loss expectations. Despite aiding patients to reduce weight by 22.7%, it fell ...

UBS analyst Trung Huynh says Novo Nordisk’s CagriSema Phase 3 topline obesity data “underwhelmed,” a positive read-through to Eli Lilly and Amgen . CagriSema achieved an ave ...

Novo Nordisk announced plans for a new trial of its CagriSema drug to explore its weight-loss potential further in 2025. The decision follows disappointing results from a late-stage trial that showed ...

Altimmune is redefining success in both obesity and MASH to position Pemvidutide in blue ocean categories. Read why I rate ...

This whitepaper explores how AAV titration and anti-AAV antibody ELISA kits streamline AAV-based gene therapy research, ...

Abstracts and poster times can be found at the American Epilepsy Society website. Saturday, December 7 CORE-VNS: Dosing and Titration of VNS Therapy™ in Contemporary Clinical Practice (1.515) – ...

(Figure S2); XPS quantitative analysis of commercial GO materials (Table S1); flowchart illustrating the experimental procedure of the acid–solvent method (Figure S3); FTIR spectra before and after ...

Department of Chemistry and Centre of Advanced Studies, Panjab University, Sector-14, Chandigarh, India 160014 ...